Paper35580929
CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy.
Xiao M and 24 others. J Immunother Cancer, 2022. Cited by 57 papers, by iCite.
Cite this record
ConductScience Library. CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy. Papers, record 35580929. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35580929
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy.
- PubMed
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adenocarcinoma | Major topic |
| Colorectal Neoplasms | Major topic |
| Melanoma | Major topic |
| Animals | |
| B7-H1 Antigen | |
| CD4-Positive T-Lymphocytes | |
| CD8-Positive T-Lymphocytes | |
| Epitopes, T-Lymphocyte | |
| Glycoproteins | |
| Humans | |
| Immune Checkpoint Inhibitors | |
| Immunotherapy | |
| Mice | |
| Ovalbumin | |
| Programmed Cell Death 1 Receptor | |
| Receptors, Antigen, T-Cell | |
| Tumor Microenvironment | |
| Vaccination |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Erratum in | 36283738 | Correction: CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy. | https://conductscience.org/library/papers/36283738 |
Source PubMed
References59
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20940398 | CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. | Cancer Res | 2010 | https://conductscience.org/library/papers/20940398 | PubMed |
| 2 | 9624004 | Help for cytotoxic-T-cell responses is mediated by CD40 signalling. | Nature | 1998 | https://conductscience.org/library/papers/9624004 | PubMed |
| 3 | 20525992 | Improved survival with ipilimumab in patients with metastatic melanoma. | N Engl J Med | 2010 | https://conductscience.org/library/papers/20525992 | PubMed |
| 4 | 31810882 | Proliferating Transitory T Cells with an Effector-like Transcriptional Signature Emerge from PD-1+ Stem-like CD8+ T Cells during Chronic Infection. | Immunity | 2019 | https://conductscience.org/library/papers/31810882 | PubMed |
| 5 | 30635236 | Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1-CD8+ Tumor-Infiltrating T Cells. | Immunity | 2019 | https://conductscience.org/library/papers/30635236 | PubMed |
| 6 | 32477338 | Bcl6 Preserves the Suppressive Function of Regulatory T Cells During Tumorigenesis. | Front Immunol | 2020 | https://conductscience.org/library/papers/32477338 | PubMed |
| 7 | 26412456 | Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. | N Engl J Med | 2015 | https://conductscience.org/library/papers/26412456 | PubMed |
| 8 | 2137372 | Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. | Cell | 1990 | https://conductscience.org/library/papers/2137372 | PubMed |
| 9 | 7525709 | Influenza and vaccinia viruses expressing malaria CD8+ T and B cell epitopes. Comparison of their immunogenicity and capacity to induce protective immunity. | J Immunol | 1994 | https://conductscience.org/library/papers/7525709 | PubMed |
| 10 | 29567705 | Cancer immunotherapy using checkpoint blockade. | Science | 2018 | https://conductscience.org/library/papers/29567705 | PubMed |
| 11 | 30057419 | CD4+ T cell help in cancer immunology and immunotherapy. | Nat Rev Immunol | 2018 | https://conductscience.org/library/papers/30057419 | PubMed |
| 12 | 29126798 | CD4+ T Cell Help Confers a Cytotoxic T Cell Effector Program Including Coinhibitory Receptor Downregulation and Increased Tissue Invasiveness. | Immunity | 2017 | https://conductscience.org/library/papers/29126798 | PubMed |
| 13 | 25858804 | Immune checkpoint blockade: a common denominator approach to cancer therapy. | Cancer Cell | 2015 | https://conductscience.org/library/papers/25858804 | PubMed |
| 14 | 18770580 | Influenza: propagation, quantification, and storage. | Curr Protoc Microbiol | 2006 | https://conductscience.org/library/papers/18770580 | PubMed |
| 15 | 21739672 | T cell exhaustion. | Nat Immunol | 2011 | https://conductscience.org/library/papers/21739672 | PubMed |
| 16 | 26406148 | Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. | N Engl J Med | 2015 | https://conductscience.org/library/papers/26406148 | PubMed |
| 17 | 27192570 | Targeting T Cell Co-receptors for Cancer Therapy. | Immunity | 2016 | https://conductscience.org/library/papers/27192570 | PubMed |
| 18 | 30676822 | CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. | Annu Rev Immunol | 2019 | https://conductscience.org/library/papers/30676822 | PubMed |
| 19 | 22790179 | Cross-presentation by dendritic cells. | Nat Rev Immunol | 2012 | https://conductscience.org/library/papers/22790179 | PubMed |
| 20 | 9740780 | Transfectant influenza A viruses are effective recombinant immunogens in the treatment of experimental cancer. | Virology | 1998 | https://conductscience.org/library/papers/9740780 | PubMed |
Cited by41
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 57 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42515567 | Synthetic Biology Strategies for the Development of Live Attenuated Influenza Viruses: Recent Advances and Applications. | Viruses | 2026 | https://conductscience.org/library/papers/42515567 | PubMed |
| 42351104 | Virus-like particles in cancer immunotherapy: bridging human and veterinary medicine through one health. | J Nanobiotechnology | 2026 | https://conductscience.org/library/papers/42351104 | PubMed |
| 42258951 | An immunogenomic classification of solid tumours reveals subtype-specific therapeutic vulnerabilities for immunotherapy. | EBioMedicine | 2026 | https://conductscience.org/library/papers/42258951 | PubMed |
| 42011487 | Vaccination with cationic liposome-encapsulated CD4 and CD8 T cell neoepitopes induces superior tumor control. | Mater Today Bio | 2026 | https://conductscience.org/library/papers/42011487 | PubMed |
| 41977251 | Immune Escape in Renal Cell Carcinoma: Latest Research and Treatment Strategies. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41977251 | PubMed |
| 41969464 | Prognostic value of systemic inflammation indices in patients with metastatic colorectal cancer treated with TAS-102: a single-center retrospective real-world study. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/41969464 | PubMed |
| 41739190 | Heterologous prime-boost immunization of AAV-based neoantigen cancer vaccine induces anti-tumor immunity to inhibit tumor growth and relapse. | Cancer Immunol Immunother | 2026 | https://conductscience.org/library/papers/41739190 | PubMed |
| 41608565 | The novel B-cell epitope peptide vaccine, MAX449, exhibits significant anti-tumor efficacy and enhances the therapeutic effects of PD-1 antibodies on tumors by modulating the activity of PMN-MDSCs. | Theranostics | 2026 | https://conductscience.org/library/papers/41608565 | PubMed |
| 41588956 | Tumor-embedded Immunity and TRM Cell Functions in Cancer. | Mini Rev Med Chem | 2026 | https://conductscience.org/library/papers/41588956 | PubMed |
| 41425703 | Immune Checkpoint Inhibitors Combined with Oncolytic Virotherapy: Synergy, Heterogeneity, and Safety in Cancer Treatment. | Oncol Res | 2025 | https://conductscience.org/library/papers/41425703 | PubMed |
| 41408237 | PD-1/PD-L1 pathway relieves incision induced acute postoperative pain via inhibiting the neuroinflammation in dorsal root ganglion of rats. | Sci Rep | 2025 | https://conductscience.org/library/papers/41408237 | PubMed |
| 41348109 | Chimeric MHC class I- and II-restricted non-self epitopes broaden antitumor T cell reactions. | J Exp Med | 2026 | https://conductscience.org/library/papers/41348109 | PubMed |
| 41137391 | DCC-2036 induces repolarization of TAMs to M1 type and enhances CD8+ T cell immunity in TNBC. | Mol Ther | 2026 | https://conductscience.org/library/papers/41137391 | PubMed |
| 41079643 | Immune Surveillance and Immune Escape in Cancer: Mechanisms and Immunotherapy. | MedComm (2020) | 2025 | https://conductscience.org/library/papers/41079643 | PubMed |
| 40860882 | Nanoengineered-based delivery systems to modulate CD4+ T cell responses in cancer: emerging paradigms in cancer immunotherapy. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40860882 | PubMed |
| 40692748 | Enhanced efficacy of immune checkpoint inhibitors with OK-432 in malignant pleural mesothelioma: A case report. | Mol Clin Oncol | 2025 | https://conductscience.org/library/papers/40692748 | PubMed |
| 40615377 | Tislelizumab (anti-PD-1) plus chemotherapy as neoadjuvant therapy for patients with stage IB3/IIA2 cervical cancer (NATIC): a prospective, single-arm, phase II study. | Signal Transduct Target Ther | 2025 | https://conductscience.org/library/papers/40615377 | PubMed |
| 40585991 | NGR-modified nanovesicles target ALKBH5 to inhibit ovarian cancer growth and metastasis. | Theranostics | 2025 | https://conductscience.org/library/papers/40585991 | PubMed |
| 40573908 | Synergistic Antitumor Effects of Caerin Peptides and Dendritic Cell Vaccines in a 4T-1 Murine Breast Cancer Model. | Vaccines (Basel) | 2025 | https://conductscience.org/library/papers/40573908 | PubMed |
| 40539075 | Construction and evaluation of a Salmonella minicell-based dendritic cell-targeted multi-epitope vaccine against Helicobacter pylori. | Front Immunol | 2025 | https://conductscience.org/library/papers/40539075 | PubMed |
Genes12
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35580929
GET https://conductscience.org/api/papers/v1/35580929/authors?page=2